FDA Approves Naproxen/Esomeprazole for Patients With Arthritis at Risk of Developing Gastric Ulcers
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




FDA Approves Naproxen/Esomeprazole for Patients With Arthritis at Risk of Developing Gastric Ulcers

NEW YORK -- May 3, 2010 -- The US Food and Drug Administration (FDA) has approved naproxen/esomeprazole (Vimovo) fixed-dose combination delayed-release tablets for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and to decrease the risk of developing gastric ulcers in patients at risk of developing nonsteroidal anti-inflammatory drug-associated gastric ulcers.

The approval was based on data from a clinical development program and results from the PN400-301 and PN400-302 studies.

In both studies, the primary end point was the cumulative incidence of gastric ulcers through 6 months. In each of the trials, patients received either naproxen/esomeprazole or enteric-coated naproxen 500 mg BID over a 6-month treatment period. Endoscopies were performed at baseline and at 1, 3, and 6 months.

Data from study PN400-301 showed a 4.1% incidence of gastric ulcers in patients taking naproxen/esomeprazole, compared with 23.1% among patients taking enteric-coated naproxen (P < .001).

Study PN400-302 showed a 7.1% incidence of gastric ulcers among patients taking naproxen/esomeprazole, compared with 24.3% of patients taking enteric-coated naproxen (P < .001).

The most commonly observed adverse events (experienced by >5% of patients in the naproxen/esomeprazole group) were erosive gastritis, dyspepsia, gastritis, diarrhoea, gastric ulcer, upper abdominal pain, and nausea.

SOURCE: AstraZeneca

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities